{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:58:09Z","timestamp":1778273889446,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,5,28]],"date-time":"2010-05-28T00:00:00Z","timestamp":1275004800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s11906-010-0119-1","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T04:24:59Z","timestamp":1274934299000},"page":"296-302","source":"Crossref","is-referenced-by-count":10,"title":["New Therapeutic Approaches to Resistant Hypertension"],"prefix":"10.1007","volume":"12","author":[{"given":"Markus P.","family":"Schlaich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray D.","family":"Esler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,28]]},"reference":[{"key":"119_CR1","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/HYPERTENSIONAHA.107.095497","volume":"50","author":"V Perkovic","year":"2007","unstructured":"Perkovic V, Huxley R, Wu Y, et al.: The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007, 50:991\u2013997.","journal-title":"Hypertension"},{"key":"119_CR2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.290.2.199","volume":"290","author":"I Hajjar","year":"2003","unstructured":"Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988\u20132000. JAMA 2003, 290:199\u2013206.","journal-title":"JAMA"},{"key":"119_CR3","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.jacc.2008.08.036","volume":"52","author":"PA Sarafidis","year":"2008","unstructured":"Sarafidis PA, Bakris GL: Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008, 52:1749\u20131757.","journal-title":"J Am Coll Cardiol"},{"key":"119_CR4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, et al.: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105\u20131187.","journal-title":"J Hypertens"},{"key":"119_CR5","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","volume":"289","author":"HR Black","year":"2003","unstructured":"Black HR, Elliott WJ, Grandits G, et al.: Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003, 289:2073\u20132082.","journal-title":"JAMA"},{"key":"119_CR6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","volume":"4","author":"WC Cushman","year":"2002","unstructured":"Cushman WC, Ford CE, Cutler JA, et al.: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002, 4:393\u2013404.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"119_CR7","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","volume":"51","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, et al.: Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403\u20131419.","journal-title":"Hypertension"},{"key":"119_CR8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","volume":"55","author":"F Souza de","year":"2010","unstructured":"de Souza F, Muxfeldt E, Fiszman R, Salles G: Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010, 55:147\u2013152.","journal-title":"Hypertension"},{"key":"119_CR9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, et al.: Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839\u2013845.","journal-title":"Hypertension"},{"key":"119_CR10","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0006-291X(03)01451-7","volume":"308","author":"JM Wood","year":"2003","unstructured":"Wood JM, Maibaum J, Rahuel J, et al.: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003, 308:698\u2013705.","journal-title":"Biochem Biophys Res Commun"},{"key":"119_CR11","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","volume":"39","author":"J Nussberger","year":"2002","unstructured":"Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002, 39:E1\u2013E8.","journal-title":"Hypertension"},{"key":"119_CR12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","volume":"111","author":"AH Gradman","year":"2005","unstructured":"Gradman AH, Schmieder RE, Lins RL, et al.: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005, 111:1012\u20131018.","journal-title":"Circulation"},{"key":"119_CR13","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2165\/00003495-200767120-00008","volume":"67","author":"JE Frampton","year":"2007","unstructured":"Frampton JE, Curran MP: Aliskiren: a review of its use in the management of hypertension. Drugs 2007, 67:1767\u20131792.","journal-title":"Drugs"},{"key":"119_CR14","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI0214276","volume":"109","author":"G Nguyen","year":"2002","unstructured":"Nguyen G, Delarue F, Burckle C, et al.: Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417\u20131427.","journal-title":"J Clin Invest"},{"key":"119_CR15","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","volume":"358","author":"HH Parving","year":"2008","unstructured":"Parving HH, Persson F, Lewis JB, et al.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433\u20132446.","journal-title":"N Engl J Med"},{"key":"119_CR16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","volume":"119","author":"SD Solomon","year":"2009","unstructured":"Solomon SD, Appelbaum E, Manning WJ, et al.: Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119:530\u2013537.","journal-title":"Circulation"},{"key":"119_CR17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","volume":"1","author":"JJ McMurray","year":"2008","unstructured":"McMurray JJ, Pitt B, Latini R, et al.: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008, 1:17\u201324.","journal-title":"Circ Heart Fail"},{"key":"119_CR18","unstructured":"Solomon SD: Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with left ventricular dysfunction: ASPIRE. Presentation No: 3019-10, presented at American College of Cardiology 59th Annual Scientific Sessions. Atlanta, GA; March 14\u201316, 2010."},{"key":"119_CR19","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","volume":"111","author":"A Fiebeler","year":"2005","unstructured":"Fiebeler A, Nussberger J, Shagdarsuren E, et al.: Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005, 111:3087\u20133094.","journal-title":"Circulation"},{"key":"119_CR20","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(01)06584-9","volume":"358","author":"MA Weber","year":"2001","unstructured":"Weber MA: Vasopeptidase inhibitors. Lancet 2001, 358:1525\u20131532.","journal-title":"Lancet"},{"key":"119_CR21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","volume":"17","author":"JB Kostis","year":"2004","unstructured":"Kostis JB, Packer M, Black HR, et al.: Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004, 17:103\u2013111.","journal-title":"Am J Hypertens"},{"key":"119_CR22","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"\u2022\u2022 Ruilope LM, Dukat A, B\u00f6hm M, et al.: Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010, 375:1255\u20131266. This is the first study to report on the safety and BP-lowering effects of an ARB\/neprilysin inhibitor combination.","journal-title":"Lancet"},{"key":"119_CR23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1042\/CS20030381","volume":"107","author":"MJ Brown","year":"2004","unstructured":"Brown MJ, Coltart J, Gunewardena K, et al.: Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004, 107:167\u2013173.","journal-title":"Clin Sci (Lond)"},{"key":"119_CR24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HJH.0b013e32800ff5d6","volume":"25","author":"PM Ambuhl","year":"2007","unstructured":"Ambuhl PM, Tissot AC, Fulurija A, et al.: A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007, 25:63\u201372.","journal-title":"J Hypertens"},{"key":"119_CR25","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(08)60381-5","volume":"371","author":"AC Tissot","year":"2008","unstructured":"\u2022 Tissot AC, Maurer P, Nussberger J, et al.: Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008, 371:821\u2013827. This study provides evidence of successful immunization against angiotensin II and associated BP-lowering effects.","journal-title":"Lancet"},{"key":"119_CR26","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","volume":"338","author":"H Krum","year":"1998","unstructured":"Krum H, Viskoper RJ, Lacourciere Y, et al.: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998, 338:784\u2013790.","journal-title":"N Engl J Med"},{"key":"119_CR27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/HYPERTENSIONAHA.108.113068","volume":"52","author":"E Raichlin","year":"2008","unstructured":"Raichlin E, Prasad A, Mathew V, et al.: Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension 2008, 52:522\u2013528.","journal-title":"Hypertension"},{"issue":"7 Pt 1","key":"119_CR28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0895-7061(02)02933-3","volume":"15","author":"R Nakov","year":"2002","unstructured":"Nakov R, Pfarr E, Eberle S: Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 2002, 15(7 Pt 1):583\u2013589.","journal-title":"Am J Hypertens"},{"key":"119_CR29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1524-6175.2007.07244.x","volume":"9","author":"HR Black","year":"2007","unstructured":"Black HR, Bakris GL, Weber MA, et al.: Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 2007, 9:760\u2013769.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"119_CR30","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","volume":"374","author":"MA Weber","year":"2009","unstructured":"\u2022\u2022 Weber MA, Black H, Bakris G, et al.: A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1423\u20131431. This study provides evidence for a potentially important role of endothelin antagonism in resistant hypertension.","journal-title":"Lancet"},{"key":"119_CR31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/01.HYP.0000111837.73693.9b","volume":"43","author":"TE Lohmeier","year":"2004","unstructured":"Lohmeier TE, Irwin ED, Rossing MA, et al.: Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 2004, 43:306\u2013311.","journal-title":"Hypertension"},{"key":"119_CR32","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jvs.2006.08.024","volume":"44","author":"KA Illig","year":"2006","unstructured":"Illig KA, Levy M, Sanchez L, et al.: An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg 2006, 44:1213\u20131218.","journal-title":"J Vasc Surg"},{"key":"119_CR33","first-page":"4626","volume":"2009","author":"EG Lovett","year":"2009","unstructured":"\u2022 Lovett EG, Schafer J, Kaufman CL: Chronic baroreflex activation by the Rheos system: an overview of results from European and North American feasibility studies. Conf Proc IEEE Eng Med Biol Soc 2009, 2009:4626\u20134630. This article presents an overview of safety and efficacy data on carotid sinus stimulation in resistant hypertension.","journal-title":"Conf Proc IEEE Eng Med Biol Soc"},{"key":"119_CR34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.avsg.2009.10.003","volume":"24","author":"LA Sanchez","year":"2010","unstructured":"Sanchez LA, Illig K, Levy M, et al.: Implantable carotid sinus stimulator for the treatment of resistant hypertension: local effects on carotid artery morphology. Ann Vasc Surg 2010, 24:178\u2013184.","journal-title":"Ann Vasc Surg"},{"key":"119_CR35","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/HYPERTENSIONAHA.109.140665","volume":"55","author":"K Heusser","year":"2010","unstructured":"Heusser K, Tank J, Engeli S, et al.: Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010, 55:619\u2013626.","journal-title":"Hypertension"},{"key":"119_CR36","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1751-7176.2009.00163.x","volume":"11","author":"KC Young","year":"2009","unstructured":"Young KC, Teeters JC, Benesch CG, et al.: Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator. J Clin Hypertens (Greenwich) 2009, 11:555\u2013563.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"119_CR37","first-page":"184","volume":"10","author":"VM Campese","year":"1997","unstructured":"Campese VM: Neurogenic factors and hypertension in chronic renal failure. J Nephrol 1997, 10:184\u2013187.","journal-title":"J Nephrol"},{"issue":"6 Pt 1","key":"119_CR38","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0895-7061(98)00030-2","volume":"11","author":"S Ye","year":"1998","unstructured":"Ye S, Gamburd M, Mozayeni P, et al.: A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998, 11(6 Pt 1):723\u2013728.","journal-title":"Am J Hypertens"},{"key":"119_CR39","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0895-7061(02)02959-X","volume":"15","author":"S Ye","year":"2002","unstructured":"Ye S, Zhong H, Yanamadala V, Campese VM: Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002, 15:717\u2013724.","journal-title":"Am J Hypertens"},{"issue":"Suppl 75","key":"119_CR40","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1046\/j.1523-1755.2000.07511.x","volume":"57","author":"VM Campese","year":"2000","unstructured":"Campese VM: Neurogenic factors and hypertension in renal disease. Kidney Int 2000, 57(Suppl 75):S2\u2013S6.","journal-title":"Kidney Int"},{"issue":"4 Pt 2","key":"119_CR41","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/01.HYP.25.4.878","volume":"25","author":"VM Campese","year":"1995","unstructured":"Campese VM, Kogosov E: Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995, 25(4 Pt 2):878\u2013882.","journal-title":"Hypertension"},{"key":"119_CR42","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0272-6386(95)90456-5","volume":"26","author":"VM Campese","year":"1995","unstructured":"Campese VM, Kogosov E, Koss M: Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995, 26:861\u2013865.","journal-title":"Am J Kidney Dis"},{"key":"119_CR43","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1001\/jama.1953.03690160001001","volume":"152","author":"RH Smithwick","year":"1953","unstructured":"Smithwick RH, Thompson JE: Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc 1953, 152:1501\u20131504.","journal-title":"J Am Med Assoc"},{"issue":"6757","key":"119_CR44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(53)91589-X","volume":"1","author":"DM Morrissey","year":"1953","unstructured":"Morrissey DM, Brookes VS, Cooke WT: Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet 1953, 1(6757):403\u2013408.","journal-title":"Lancet"},{"key":"119_CR45","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1161\/HYPERTENSIONAHA.109.138610","volume":"54","author":"MP Schlaich","year":"2009","unstructured":"Schlaich MP, Sobotka PA, Krum H, et al.: Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009, 54:1195\u20131201.","journal-title":"Hypertension"},{"key":"119_CR46","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","volume":"373","author":"H Krum","year":"2009","unstructured":"\u2022\u2022 Krum H, Schlaich M, Whitbourn R, et al.: Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275\u20131281. This study presents the first data on the safety and efficacy of a novel catheter-based approach to functionally denervate the human kidney, demonstrating a favorable safety profile and substantial and sustained reductions in BP.","journal-title":"Lancet"},{"key":"119_CR47","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMc0904179","volume":"361","author":"MP Schlaich","year":"2009","unstructured":"Schlaich MP, Sobotka PA, Krum H, et al.: Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009, 361:932\u2013934.","journal-title":"N Engl J Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-010-0119-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-010-0119-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-010-0119-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:14:24Z","timestamp":1559420064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-010-0119-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,28]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["119"],"URL":"https:\/\/doi.org\/10.1007\/s11906-010-0119-1","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,28]]}}}